



This report is prepared for the Warsaw Stock Exchange SA within the framework of the Analytical Coverage Support Program 3.0.

Daily 5.IX.2022

Company	LT fundamental recommendation	12M EFV (PLN)	ST market-relative bias	Analyst
BioMaxima	Not rated	37.1	Not rated	Sylwia Jaśkiewicz, CFA Mikołaj Stępień

Event: Buyback update

The Company informed that it purchased 153,500 shares (3.5% of the share capital) for PLN 4.3 million in the pending buyback which implies an average price per share at c. PLN 28.05. BioMaxima has spent already 86% of the amount earmarked for the buyback (PLN 5 million).

Expected impact: *Neutral.*

The report is not a recommendation within the meaning of Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest.